Originally Aired: September 30, 2020
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
For many years Chinese hamster ovary select CHO) cells have been the cornerstone of the success of biopharmaceutical proteins. Their flexibility and adaptability to bioreactor culture conditions, compared to other mammalian systems, make them the system of choice for one of the most successful protein therapeutic classes, monoclonal antibodies. In recent years, cell line engineering efforts have generated improved host cell lines for therapeutic production that maximize protein expression and increase their robustness in bioproduction. One example is the Horizon Discovery’s CHOSOURCE™ GS knockout cell line, in which the genetic ablation of the glutamine synthetase select GS) gene facilitates the selection of highly expressing clones with optimal performance during cell line development. This GS knockout cell line is of high value to the biopharmaceutical industry, looking to create efficient and safe therapies for a large variety of disease states.
In this GEN webinar, we will hear about Elanco Animal Health’s experience implementing the CHOSOURCE GS knockout cell line in building a biotherapeutics research program in animal health. While the species of the proteins expressed are different, most of the methods and process challenges remain the same between human and veterinary pharma. Our presenters will discuss their process for evaluating growth conditions, transfection methods, clonal cell line development, and productivity assessments. We will also hear about the gene-editing options available to customize expression hosts to suit specific needs during discovery, development, and protein production.
A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelists.
Produced with support from:
Allyn Spear, PhD
Principle Research Scientist,
Elanco Animal Health
Mario Pereira, PhD
Field Application Scientist